Want to see IXHL full AI Analyst Report?
IXHL Stock Chart & Stats
$3.75
$0.09(3.05%)
At close: 4:00 PM EDT
$3.75
$0.09(3.05%)
Day’s Range― - ―
52-Week Range$2.49 - $14.93
Previous CloseN/A
Volume29.18K
Average Volume (3M)80.68K
Market Cap
$38.89M
Enterprise Value-$17.69M
Total Cash (Recent Filing)$67.71M
Total Debt (Recent Filing)$96.00K
Price to Earnings (P/E)―
Beta4.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,544,627
10 Day Avg. Volume62,202
30 Day Avg. Volume80,684
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-3.40
Enterprise Value/Market Cap-0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressProgressing IHL-42X into an active Phase 2 dose-optimization study, supported by earlier positive efficacy data and Fast Track status, strengthens the lead program’s development path. This creates a clearer route toward Phase 3 planning and potential future commercialization if execution remains successful.
Intellectual Property ProtectionThe granted U.S. patent provides extended protection for IHL-42X compositions and treatment methods through 2040. If the candidate reaches commercialization, this protection could support market exclusivity, improve the asset’s strategic value, and help defend returns on development investment.
Debt-free LiquidityA substantial cash position, no debt, and more than A$11.2 million of non-dilutive funding provide financial flexibility to advance clinical programs without immediate leverage pressure. This strengthens runway and allows management to fund development while preserving balance-sheet capacity.
Bears Say
Pre-commercial Revenue BaseThe company remains pre-commercial, with revenue minimal and inconsistent and reaching zero in the latest annual period. Without meaningful operating revenue, near-term financial performance depends primarily on clinical progress and future commercialization rather than an established sales engine.
Persistent Cash BurnConsistently negative operating and free cash flow means current activities consume cash rather than fund themselves. Even with recent improvement, continued clinical development will require ongoing financial support, which can constrain capital allocation and increase dependence on future funding sources.
Execution-dependent PipelineThe key value drivers are still clinical-stage programs, including a Phase 2 study intended to inform later Phase 3 development. Until those programs produce further evidence and advance toward approval, the business remains exposed to development execution and commercialization uncertainty.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.49 and its highest was $14.93 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $38.89M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Overvalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 12,544,627 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IXHL Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.38%
12-Months-Change
Fundamentals
Return on Equity
-27.42%
Trailing 12-Months
Asset Growth
256.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.